Food and Drug Supervisory Agency (Badan POM) Gives Green Light for Phase 1 Merah Putih Vaccine Clinical Test UNAIR

The Food and Drug Supervisory Agency (Badan POM) has approved the first phase of clinical trials for the Merah Putih vaccine developed by Universitas Airlangga (Unair) with PT Biotis Pharmaceutical.

"We inform you that approval has been given to carry out clinical trials for the Merah Putih vaccine," said Head of the POM Agency, Penny K. Lukito in a press conference broadcast via YouTube. The Merah Putih Vaccine uses an inactivated virus platform. The Merah Putih vaccine is a vaccine developed by Indonesian researchers. "This time it is the Merah Putih vaccine with an inactivated virus platform developed by Unair and PT Biotis," he said. Previously, Penny said that the clinical trial of the first phase of the Merah Putih vaccine began in early February 2022. This phase of clinical trials is estimated to be completed in June 2022. In the same month, it is possible that the Merah Putih vaccine will be able to obtain an Emergency Use Authorization (EUA) permit. According to Penny, the implementation of phase 3 clinical trials for the Merah Putih vaccine could be paralleled with clinical trials for boosters. This booster clinical trial can be carried out if you have obtained some of the clinical trial data for the Phase 3 Red and White vaccine.

|•SOURCE•| Articles :MERDEKA | Image :SETKAB |

READ MORE

|• NATIONAL •|Government Extends Tax Incentives
|• INTERNATIONAL •|Omicron BA2 Subvariant More Contagious
|• BANKING •|Preparing For WFH Due To Omicron
|• POLITICS •|Indonesia Economic Endurance Test.
|• SCIENCE •|Bill Gates is Outspoken About Vaccine